References
- Avastin. Summary of product characteristics [ updated 2016 Oct; cited 2017 Feb]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf
- Avastin. Prescribing information [ updated 2015 Sep; cited 2016 Oct]. Available from: http://www.gene.com/medical-professionals/medicines/avastin
- Holmes DI, Zachary I. The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol. 2005;6:209.
- US Food and Drug Administration (FDA). Information for industry (biosimilars) [ cited 2016 Oct]. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm241720.html
- Leung LK, Mok K, Liu C, et al. What do oncologists need to know about biosimilar products? Chin J Cancer. 2016;35:91.
- McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. 2012;91:405–417.
- European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues [ cited 2016 Oct]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf
- European Medicines Agency. Avastin: EPAR - scientific discussion [ cited 2017 May] Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000582/WC500029262.pdf